Rifabutin reduces the
plasma levels of
itraconazole. Uveitis was attributed to the concurrent use of
rifabutin and
itraconazole in one report.
Ketoconazole is predicted to interact similarly.
Information is sparse, but based on what is known monitor for reduced antifungal activity, raising the azole dosage as necessary, and watch for increased
rifabutin levels and
toxicity (in particular uveitis).